R/R BCP 急性淋巴细胞白血病中 CD19 靶向免疫治疗后 CD19 阴性复发的发生率：综述

There are inconsistencies in the reporting of CD19 antigen status following treatment with CD19-targeted therapies. A majority of evidence comes from studies reporting small sample sizes. In this review, we systematically summarize published studies that have reported rates of CD19-negative relapse after treatment with either blinatumomab or CD19-directed CAR T-cell therapy and report the rates of CD19-negative relapse when evaluated in a standardized way across trials.

CD19-negative relapse appears to occur more commonly in relapses following CAR T-cell therapy compared with blinatumomab, whether proportions are calculated among all treated patients (8. 7% vs 4. 5%) or among patients who relapse (30% vs 22. 5%). The median (range) duration of follow-up was 29.

3 (17. 4-50. 8) and 20. 4 (6. 9-49. 0) months for publications on blinatumomab ( n = 10) and CAR T-cell therapies ( n = 23), respectively. There is a need for standardized reporting of CD19 antigen status in the setting of relapse following novel immunotherapies to inform clinical practice.